FDA approves Novartis osteoarthritis treatment

10/23/2007 | Forbes · Reuters

Novartis AG's topical treatment for osteoarthritis, called Voltaren Gel, was awarded FDA approval, the company announced Monday. Clinical trials showed that the nonsteroidal anti-inflammatory drug can reduce pain in both the knees and joints of the hands by 51% with minimal side effects.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID